Most cited papers from Institut Claudius Regaud

Institut Claudius Regaud

What are the most cited papers from Institut Claudius Regaud?

The most cited paper from Institut Claudius Regaud is "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer" (Thierry Conroy, Françoise Desseigne, Marc Ychou et al., 2011), with 7,927 citations. Next come "Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma" (4,813) and "Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study" (3,072).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 370 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine Open access	11 May 2011	7,927
2	Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma Bernard J. Escudier, Tim G Eisen, Walter Michael Stadler et al. · New England Journal of Medicine Open access	10 Jan 2007	4,813
3	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study Aurélien Marabelle et al. · Journal of Clinical Oncology Open access	4 Nov 2019	3,072
4	Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study Aurélien Marabelle et al. · The Lancet Oncology Open access	10 Sep 2020	2,600
5	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group Antonio Pierangelo Palumbo et al. · Journal of Clinical Oncology Open access	3 Aug 2015	2,243
6	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Bernard J. Escudier, Anna Pluzanska, P. Koralewski et al. · The Lancet	Dec 2007	2,234
7	Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation Jennifer Keating Litton, Hope S. Rugo, Johannes Ettl et al. · New England Journal of Medicine Open access	15 Aug 2018	2,198
8	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer Aditya Bardia et al. · New England Journal of Medicine Open access	21 Apr 2021	1,671
9	Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy Carola Hermine Ries et al. · Cancer Cell Open access	Jun 2014	1,404
10	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J. Mazieres et al. · Annals of Oncology Open access	15 May 2019	1,390
11	Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial Christophe Le Tourneau et al. · The Lancet Oncology	3 Sep 2015	1,144
12	Cancer-Associated Adipocytes Exhibit an Activated Phenotype and Contribute to Breast Cancer Invasion Béatrice Dirat, Ludivine Bochet, Marta Dabek et al. · Cancer Research Open access	31 Mar 2011	1,142
13	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas Michael Weller et al. · The Lancet Oncology Open access	5 May 2017	1,122
14	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study Hyun Cheol Chung, Willeke Ros, Jean‐Pierre Delord et al. · Journal of Clinical Oncology Open access	3 Apr 2019	1,083
15	Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy Antonella Sistigu et al. · Nature Medicine	26 Oct 2014	1,063
16	Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma Sylvie Négrier, Bernard J. Escudier, Christine Lasset et al. · New England Journal of Medicine Open access	30 Apr 1998	972
17	Exosomes as new vesicular lipid transporters involved in cell–cell communication and various pathophysiologies Michel Record, Kévin Carayon, Marc Poirot et al. · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids	16 Oct 2013	866
18	Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer Leisha A. Emens, Cristina Alava Cruz, Joseph P. Eder et al. · JAMA Oncology Open access	18 Sep 2018	801
19	Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer Nicholas C. Turner et al. · New England Journal of Medicine Open access	31 May 2023	780
20	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma Michael Weller, Martin J. van den Bent, Kirsten Hopkins et al. · The Lancet Oncology Open access	27 Jul 2014	767
21	Genomic characterization of metastatic breast cancers François Bertucci et al. · Nature	May 2019	755
22	Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial François‐Clément Bidard et al. · Journal of Clinical Oncology Open access	18 May 2022	754
23	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study Thomas Bachelot, Gilles Romieu, Mario Campone et al. · The Lancet Oncology	Nov 2012	748
24	Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Gwénaëlle Gravis et al. · The Lancet Oncology	8 Jan 2013	747
25	Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer Martin Jean Schlumberger, Bogdan Catargi, Isabelle Borget et al. · New England Journal of Medicine Open access	2 May 2012	698
26	Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres Martine Pressoir, S Desné, D. Berchery et al. · British Journal of Cancer Open access	16 Feb 2010	679
27	Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer Nancy U. Lin et al. · Clinical Cancer Research Open access	15 Feb 2009	666
28	Classification of radical hysterectomy Denis Querleu, C. Paul Morrow · The Lancet Oncology	Mar 2008	658
29	Dermatologic Reactions to Immune Checkpoint Inhibitors Vincent Sibaud · American Journal of Clinical Dermatology	18 Dec 2017	624
30	Multicenter Randomized Trial of Adjuvant Fluorouracil and Folinic Acid Compared With Surgery Alone After Resection of Colorectal Liver Metastases: FFCD ACHBTH AURC 9002 Trial Guillaume Portier, Dominique Elias, Olivier Bouché et al. · Journal of Clinical Oncology	30 Oct 2006	583
31	Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients Elisabeth Modigliani, Régis Cohen, José‐Marie Campos et al. · Clinical Endocrinology	Mar 1998	578
32	Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO) Marcos Ballester, Gil Dubernard, Fabrice R Lecuru et al. · The Lancet Oncology	13 Apr 2011	574
33	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors Scott T. Tagawa, Arjun Vasant Balar, Daniel Peter Petrylak et al. · Journal of Clinical Oncology Open access	30 Apr 2021	553
34	Exosomes as intercellular signalosomes and pharmacological effectors Michel Record, Caroline Subra, Sandrine Silvente‐Poirot et al. · Biochemical Pharmacology Open access	7 Mar 2011	539
35	Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial Jean‐Sébastien Frenel, Christophe Le Tourneau, Bert H. O’Neil et al. · Journal of Clinical Oncology	2 Nov 2017	538
36	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial Sylvie Bonvalot et al. · The Lancet Oncology Open access	8 Jul 2019	537
37	Adipocyte-Derived Fibroblasts Promote Tumor Progression and Contribute to the Desmoplastic Reaction in Breast Cancer Ludivine Bochet, Camille Lehuédé, Stéphanie Dauvillier et al. · Cancer Research	Aug 2013	530
38	First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin Jim Cassidy, Chris J. Twelves, Eric Van Cutsem et al. · Annals of Oncology Open access	Apr 2002	529
39	Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer Ludovic Martinet, Ignacio Garrido, Thomas Filleron et al. · Cancer Research	16 Aug 2011	526
40	Human renal function maturation: a quantitative description using weight and postmenstrual age Malin M. Rhodin, Brian Joseph Anderson, A. Michael Peters et al. · Pediatric Nephrology	9 Oct 2008	497
41	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial José Manuel Trigo et al. · The Lancet Oncology	27 Mar 2020	488
42	Implication of Mitochondrial Hydrogen Peroxide Generation in Ceramide-induced Apoptosis Anne Quillet‐Mary, Jean‐Pierre Jaffrézou, V Mansat et al. · Journal of Biological Chemistry Open access	Aug 1997	485
43	Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial Hope S. Rugo, Aditya Bardia, Frederik Marmé et al. · The Lancet Open access	23 Aug 2023	475
44	Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial Gwénaëlle Gravis, Jean‐Marie Boher, Florence Joly et al. · European Urology	21 Nov 2015	465
45	70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial V. Beckendorf, Stephane Gilles Guerif, É. Le Prisé et al. · International Journal of Radiation OncologyBiologyPhysics	15 Dec 2010	459
46	Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies Hyun Cheol Chung et al. · Journal of Thoracic Oncology Open access	20 Dec 2019	445
47	Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy LM Mir, LF Glass, Gregor Serša et al. · British Journal of Cancer Open access	Jun 1998	444
48	Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients Myriam Delaunay et al. · European Respiratory Journal Open access	Aug 2017	427
49	Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) Fabrice André, Thomas Bachelot, Frédéric Commo et al. · The Lancet Oncology	6 Feb 2014	418
50	Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis Céline Lefèbvre et al. · PLoS Medicine Open access	27 Dec 2016	413

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.